Trial
NCT03420222
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Intermittent Explosive Disorder
Intervention
AVP-786
Why stopped
Due to limited enrollment (N=10), this clinical trial was terminated by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-24